About Biocon Biologics Limited
Data last updated:
Biocon Biologics Limited is a public limited company based in Bengaluru, Karnataka, India, a subsidiary of Biocon Limited. It operates in the API manufacturers segment of the pharmaceuticals sector. It was incorporated on 08 June 2016 and has been in existence for over 10 years.
The company is registered with the Registrar of Companies (ROC), Bangalore, under CIN U24119KA2016PLC093936. Its GSTIN is 29AAGCB7796M2ZO (Karnataka). The company holds 21 GST registrations, of which 19 are active.
The company has an authorised share capital of ₹3,500 Cr and a paid-up capital of ₹1,819.87 Cr. It was formerly known as Biocon Biologics India Limited. It is led by directors including Kiran Mazumdar Shaw (Whole-Time Director) and Bobby Kanubhai Parikh.
Its last annual general meeting (AGM) was held on 25 July 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at Biocon House Ground Floor Tower – 3 Semicon Park Electronic City Phase – II Hosur Road, Bengaluru, Karnataka, India – 560100.
As per the financials filed for FY 2025, the company reported a revenue of ₹10,144 Cr, a growth of 13% compared to the previous year. For the same year it recorded a net profit of ₹889.6 Cr (net margin 8.8%) and EBITDA of ₹3,108 Cr (EBITDA margin 30.6%). Revenue has grown at a compounded annual rate (CAGR) of 43% over three years and 34% over five years.
The company has about 5,280 employees on its provident fund (EPFO) records.
As per MCA filings, the company has open charges of ₹9,543.66 Cr and satisfied charges of ₹18,987 Cr on record. Court records list 40 cases involving the company, including 36 filed by the company and 2 filed against it; 12 cases are pending. The company has 38 deals on record (22 secondary share transfers, 8 funding rounds, 4 convertible or debt financings), with disclosed funding of ₹15,829 Cr; the latest was in January 2025. Its 10 peer companies in the Pharma industry (API Manufacturers, Biologics) are compared by revenue, 5 larger and 5 smaller; the largest is Sun Pharmaceutical Industries Limited with revenue of ₹54,543 Cr. The company has 34 MSME Form 1 returns on record between 2019 and 2024, listing 28,937 overdue payments to 1,111 micro and small suppliers.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website biocon.com.
- EmailLocked
- TelephoneLocked
- Website
- Social Media
- Registered AddressBiocon House Ground Floor Tower – 3 Semicon Park Electronic City Phase – II Hosur Road, Bengaluru, Karnataka, India – 560100
- IndustryPharma, API Manufacturers
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
- One PDF report, delivered after checkout
Business Activity of Biocon Biologics Limited
The main business activity of Biocon Biologics is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | Locked |
Business activity turnover details
Turnover share and past changes in activity are in the company report.
- Turnover contribution
- Historical classifications
- Filing-level activity changes
Verified entity values are shown only after access is granted.
Financials of Biocon Biologics Limited FY 2025 filings available
Biocon Biologics Limited reported revenue of ₹10,144 Cr (up 13% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR) of Biocon Biologics Limited
Revenue has grown at a compounded annual rate (CAGR) of 34% over five years, including 13% growth in the latest year. EBITDA rose 41% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary of Biocon Biologics Limited
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | •••• | •••• | •••• | •••• | •••• |
| Other Income | •••• | •••• | •••• | •••• | •••• |
| Total Revenue | •••• | •••• | •••• | •••• | •••• |
| Cost of Materials Consumed | •••• | •••• | •••• | •••• | •••• |
| Employee Benefit Expense | •••• | •••• | •••• | •••• | •••• |
| Finance Costs | •••• | •••• | •••• | •••• | •••• |
| Depreciation and Amortisation | •••• | •••• | •••• | •••• | •••• |
| Other Expenses | •••• | •••• | •••• | •••• | •••• |
| Total Expenses | •••• | •••• | •••• | •••• | •••• |
| EBITDA | ₹3,108 Cr | •••• | •••• | •••• | •••• |
| Profit Before Tax | •••• | •••• | •••• | •••• | •••• |
| Tax Expense | •••• | •••• | •••• | •••• | •••• |
| Net Profit (PAT) | ₹889.6 Cr | •••• | •••• | •••• | •••• |
| Balance Sheet | |||||
| Share Capital | •••• | •••• | •••• | •••• | •••• |
| Reserves and Surplus | •••• | •••• | •••• | •••• | •••• |
| Net Worth (Total Equity) | •••• | •••• | •••• | •••• | •••• |
| Long-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Short-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Trade Payables | •••• | •••• | •••• | •••• | •••• |
| Total Liabilities | •••• | •••• | •••• | •••• | •••• |
| Fixed Assets | •••• | •••• | •••• | •••• | •••• |
| Investments | •••• | •••• | •••• | •••• | •••• |
| Inventories | •••• | •••• | •••• | •••• | •••• |
| Trade Receivables | •••• | •••• | •••• | •••• | •••• |
| Cash and Bank Balance | •••• | •••• | •••• | •••• | •••• |
| Total Assets | •••• | •••• | •••• | •••• | •••• |
Financial Ratios of Biocon Biologics Limited
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 30.6% | •••• | •••• | •••• | •••• |
| Net Profit Margin | 8.8% | •••• | •••• | •••• | •••• |
| Return on Equity (ROE) | •••• | •••• | •••• | •••• | •••• |
| Return on Capital Employed (ROCE) | •••• | •••• | •••• | •••• | •••• |
| Return on Assets (ROA) | •••• | •••• | •••• | •••• | •••• |
| Liquidity and Debt | |||||
| Current Ratio | •••• | •••• | •••• | •••• | •••• |
| Quick Ratio | •••• | •••• | •••• | •••• | •••• |
| Debt-to-Equity Ratio | •••• | •••• | •••• | •••• | •••• |
| Interest Coverage Ratio | •••• | •••• | •••• | •••• | •••• |
| Efficiency and Growth | |||||
| Asset Turnover | •••• | •••• | •••• | •••• | •••• |
| Receivable Days | •••• | •••• | •••• | •••• | •••• |
| Payable Days | •••• | •••• | •••• | •••• | •••• |
| Inventory Days | •••• | •••• | •••• | •••• | •••• |
| Revenue Growth | •••• | •••• | •••• | •••• | •••• |
| Net Profit Growth | •••• | •••• | •••• | •••• | •••• |
Paid data: the figures shown as dots are available after purchase of the company report. Figures as filed with the MCA in Form AOC-4. The full year-wise statements and ratios of Biocon Biologics are in the company report.
Financial statements from FY 2017
Earlier years and trend charts are in the company report.
- Income statements
- Balance sheets
- Cash-flow statements
- Ratios and benchmarks
Verified entity values are shown only after access is granted.
Peer Comparison of Biocon Biologics Limited
Biocon Biologics Limited is compared with the companies closest to it by revenue in the Pharma industry (API Manufacturers, Biologics). Net profit, margin and employee counts of each company are in the company report.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited Listed | ₹54,543 Cr (FY 2025) | •••• | •••• | 9.0% | •••• | Vadodara, Gujarat, India |
| Cipla Limited Listed | ₹28,409 Cr (FY 2025) | •••• | •••• | 7.0% | •••• | Mumbai, Maharashtra, India |
| Lupin Limited Listed | ₹22,904 Cr (FY 2025) | •••• | •••• | 14.0% | •••• | Mumbai, Maharashtra, India |
| Hetero Labs Limited | ₹16,537 Cr (FY 2025) | •••• | •••• | 13.0% | •••• | Hyderabad, Telangana, India |
| Glenmark Pharmaceuticals Limited Listed | ₹13,435 Cr (FY 2025) | •••• | •••• | 6.0% | •••• | Mumbai, Maharashtra, India |
| Biocon Biologics Limited this company | ₹10,144 Cr (FY 2025) | •••• | •••• | 13.0% | •••• | Bengaluru, Karnataka, India |
| Divi's Laboratories Limited Listed | ₹9,712 Cr (FY 2025) | •••• | •••• | 19.0% | •••• | Hyderabad, Telangana, India |
| Macleods Pharmaceuticals Ltd | ₹9,671.68 Cr (FY 2025) | •••• | •••• | 5.0% | •••• | Mumbai, Maharashtra, India |
| Ipca Laboratories Limited Listed | ₹9,032.39 Cr (FY 2025) | •••• | •••• | 15.0% | •••• | Mumbai, Maharashtra, India |
| Deccan Fine Chemicals (India) Private Limited | ₹8,738.51 Cr (FY 2024) | •••• | •••• | -1.0% | •••• | Hyderabad, Telangana, India |
| Emcure Pharmaceuticals Limited | ₹7,963.26 Cr (FY 2025) | •••• | •••• | 19.0% | •••• | Pune, Maharashtra, India |
Peers are the five companies nearest above and the five nearest below Biocon Biologics by revenue in the Pharma industry (API Manufacturers, Biologics), from the latest filed financials of each company. Net profit, margin and employee counts of each peer are in the company report.
Auditor Details of Biocon Biologics Limited
Biocon Biologics Limited is audited by B S R & Co. LLP for the financial year 2023.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| B S R & Co. LLP | Locked | Locked | Locked |
Complete auditor history
Appointment and cessation dates and past auditor changes are in the company report.
- Appointment status
- Appointment dates
- Cessation dates
- Auditor changes
Verified entity values are shown only after access is granted.
Board of Directors and KMP of Biocon Biologics Limited
Biocon Biologics Limited currently reports 8 directors and 1 key managerial person. 22 former directors have served the organization.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Bobby Kanubhai Parikh | Director | 01 Aug 2019 | 7 Years 2 Months | Current |
| Kiran Mazumdar Shaw | Whole-Time Director | 08 Jun 2016 | 10 Years 4 Months | Current |
| Daniel Mark Bradbury | Director | 01 Aug 2019 | 7 Years 2 Months | Current |
| Rajiv Malik | Nominee Director | 29 Nov 2022 | 3 Years 10 Months | Current |
| Peter Baron Piot Also directs: Biological E. Limited | Director | 21 Jan 2021 | 5 Years 8 Months | Current |
| Shreehas Pradeep Tambe Also directs: Biocon Limited | Ceo | 05 Dec 2022 | 3 Years 10 Months | Current |
Ownership and Shareholding of Biocon Biologics Limited
Shareholding and ownership data
Promoter, institutional, public and beneficial ownership figures are in the company report.
- Ownership categories
- Historical changes
- Group structure
- FII and DII holdings
Verified entity values are shown only after access is granted.
Charges & Borrowings of Biocon Biologics Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 09 Dec 2024 | Others | ₹2,734.9 Cr | Open |
| 22 Nov 2024 | Others | ₹6,808.76 Cr | Open |
| 06 Mar 2023 | The Hongkong and Shanghai Banking Corporation Limited | ₹9,841.76 Cr | Satisfied |
| 03 Mar 2023 | Others | ₹7,947.94 Cr | Satisfied |
| 13 Sep 2021 | Others | ₹200 Cr | Satisfied |
Total charge records: 8 View all charges
Deals & Funding of Biocon Biologics Limited
Biocon Biologics Limited has 38 deals on record (22 secondary share transfers, 8 funding rounds, 4 convertible or debt financings), with disclosed funding of ₹15,829 Cr; the latest was in January 2025.
Deals on record (5 of 38)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Jan 2025 | Secondary share transfer | Undisclosed | Buyer: Biocon Limited Seller: ADQ |
| Mar 2024 | Acquisition | ₹1,242 Cr | Buyer: Eris Lifesciences Limited Seller: Biocon Biologics Limited |
| Nov 2023 | Acquisition | ₹366 Cr | Buyer: Eris Lifesciences Limited Seller: Biocon Biologics Limited |
| Jun 2023 | Secondary share transfer | Undisclosed | Buyer: Biocon Limited Seller: Biocon Limited & Murali Krishnan |
| May 2023 | Secondary share transfer | Undisclosed | Buyer: Serum Institute Life Sciences Private Limited Seller: Biocon Pharma Limited |
Full deal history
All 38 deals with amounts, valuations, instruments and every party are in the company report.
- Every funding round and share transfer
- Amounts and valuations
- Investors, buyers and sellers
- Instruments and deal dates
Verified entity values are shown only after access is granted.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal Cases of Biocon Biologics Limited
Biocon Biologics Limited has 40 court cases on record: 36 filed by Biocon Biologics, 2 filed against it, 2 where it is another party. 12 cases are pending and 28 are disposed. Status as checked between 21 Sep 2026 and 04 Oct 2026.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 31 | 0 | 7 |
| High courts | 9 | 2 | 5 |
Cases on record (5 of 40)
| Court | Type of case | Party | Status |
|---|---|---|---|
| High Court of Rajasthan | Interim or miscellaneous application | Filed by the company against Rajasthan Medical Services Corporation Limited | Pending |
| High Court of Rajasthan | Writ petition | Filed by the company against Rajasthan Medical Services Corporation Limited | Pending |
| District court, BENGALURU, Karnataka | Criminal complaint | Filed by the company against Aadhicaizen Medicine Point (OPC) Private Limited | Pending |
| High Court of Rajasthan | Interim or miscellaneous application | Filed by the company against Rajasthan Medical Services Corporation Limited | Disposed |
| High Court of Rajasthan | Court case (SAW) | Filed by the company against Rajasthan Medical Services Corporation Limited | Disposed |
Full case history
All 40 cases with case numbers, court, year-wise trend, opposite parties and decision dates are in the company report.
- Every case with its case number
- Year-wise trend
- Opposite parties
- Decision dates and orders
Verified entity values are shown only after access is granted.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME Payment Delays by Biocon Biologics Limited
Biocon Biologics Limited has 34 MSME Form 1 returns on record between 2019 and 2024, listing 28,937 overdue payments to 1,111 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 1,111)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| Ef Site Technologies Private Limited | •••• | •••• | •••• |
| an individual supplier | •••• | •••• | •••• |
| an individual supplier | •••• | •••• | •••• |
| Tempcon Express Private Limited | •••• | •••• | •••• |
| Aic Enterprises Private Limited | •••• | •••• | •••• |
Full MSME payment history
Every supplier, amount and due date from all 34 MSME Form 1 returns is in the company report.
- Every reported supplier due
- Amounts and due dates
- Reasons given in each return
- Period-by-period history
Verified entity values are shown only after access is granted.
Individuals and sole proprietors among the suppliers are not named. Amounts, due dates and filing dates are in the company report.
Employees and EPFO Compliance at Biocon Biologics Limited
Biocon Biologics Limited has a workforce of 5,280 employees as of Apr 02, 2024.
Employee and EPFO history
Monthly headcount, contribution history and filing status are in the company report.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
CIN History of Biocon Biologics Limited
Biocon Biologics has one previous CIN (Corporate Identification Number): U24119KA2016FLC093936. The current CIN is U24119KA2016PLC093936, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| U24119KA2016PLC093936 | Current |
| U24119KA2016FLC093936 | Previous |
News related to Biocon Biologics Limited
Recent Activity on Biocon Biologics Limited
Biocon Biologics Limited has 28 board changes on record since 2016: 11 appointments and 17 cessations. The latest: Akhilesh Kumar Nand was appointed as Company Secretary on 06 Aug 2024.
36 earlier events are listed in the company report.
Credit Ratings, Litigation & Regulatory Alerts for Biocon Biologics Limited
Credit ratings, litigation, and regulatory alerts
Credit ratings, court records and regulatory alerts are in the company report.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Biocon Biologics Limited
Corporate group structure
Parent, subsidiary, associate and joint venture records with holdings are in the company report.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
GST Compliance of Biocon Biologics Limited
Biocon Biologics has 21 GST registrations: 19 active and 2 cancelled or inactive. The first 4 active GSTINs are listed below.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 29AAGCB7796M2ZO | Karnataka | Active | 01 Jul 2017 |
| 29AAGCB7796M3ZN | Karnataka | Active | 23 Sep 2017 |
| 29AAGCB7796M5ZL | Karnataka | Active | 03 Jun 2019 |
| 37AAGCB7796M1ZS | Andhra Pradesh | Active | 12 Jun 2019 |
GST registrations and filing compliance
State-wise GST registrations, return filing status and HSN or SAC codes are in the company report.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Biocon Biologics Limited
MCA filings and documents
Filed forms, annual returns, financial statements and charge filings with their dates are in the company report.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Biocon Biologics Limited
Biocon Biologics is an active public limited company based in Bengaluru, Karnataka, India. The company works in api manufacturers, within the pharma industry. It was incorporated on 08 June 2016 (10+ years old) and is registered under CIN U24119KA2016PLC093936.
Biocon Biologics reported revenue of ₹10,144 Cr for FY 2025 (up 13% YoY).
Biocon Biologics has 9 current directors and KMP:
- Kiran Mazumdar Shaw - Whole-Time Director
- Bobby Kanubhai Parikh - Director
- Daniel Mark Bradbury - Director
- Rajiv Malik - Nominee Director
- Peter Baron Piot - Director
- Nivruti Rai - Director
- Arun Suresh Chandavarkar - Director
- Thomas Jason Roberts - Director
- Shreehas Pradeep Tambe - Ceo
Biocon Biologics reported a net profit of ₹889.6 Cr (net margin 8.8%) and EBITDA of ₹3,108 Cr (EBITDA margin 30.6%) for FY 2025, as per its filed financial statements.
The compounded annual growth rate (CAGR) of the revenue of Biocon Biologics is 43% over three years and 34% over five years. In the latest year (FY 2025) revenue rose 13%. CAGR is the steady yearly rate that links the first and the last year.
The GSTIN of Biocon Biologics is 29AAGCB7796M2ZO, registered in Karnataka. The company has 21 GST registrations in all, of which 19 are active and 2 are cancelled or inactive. Other active GSTINs include 29AAGCB7796M3ZN (Karnataka), 29AAGCB7796M5ZL (Karnataka), 37AAGCB7796M1ZS (Andhra Pradesh).
The CIN (Corporate Identification Number) of Biocon Biologics is U24119KA2016PLC093936. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Biocon Biologics has 40 court cases on record: 36 filed by the company and 2 filed against it. 12 are pending. Most are in the district courts.
Biocon Biologics was incorporated on 08 June 2016, making it 10+ years old. It is registered with the Registrar of Companies, Bangalore.
Biocon Biologics has 38 deals on record (22 secondary share transfers, 8 funding rounds, 4 convertible or debt financings), with disclosed funding of ₹15,829 Cr; the latest was in January 2025.
The peers of Biocon Biologics by revenue are Sun Pharmaceutical Industries Limited, Cipla Limited, Lupin Limited, Hetero Labs Limited, Glenmark Pharmaceuticals Limited and 5 more, all in the Pharma industry (API Manufacturers, Biologics).
Akhilesh Kumar Nand was appointed as Company Secretary on 06 Aug 2024. Deepika Srivastava ceased to be Company Secretary on 31 Jul 2024. John Russell Fotheringham Walls ceased to be Director on 07 Jun 2024. Biocon Biologics has 28 board changes on record in total.